Literature DB >> 27026092

Impact of Comorbidities on Acute Injury and Recovery in Preclinical Stroke Research: Focus on Hypertension and Diabetes.

Adviye Ergul1,2,3, Sherif Hafez4,5,6, Abdelrahman Fouda4,5, Susan C Fagan4,5,7.   

Abstract

Human ischemic stroke is very complex, and no single preclinical model can comprise all the variables known to contribute to stroke injury and recovery. Hypertension, diabetes, and hyperlipidemia are leading comorbidities in stroke patients. The use of predominantly young adult and healthy animals in experimental stroke research has created a barrier for translation of findings to patients. As such, more and more disease models are being incorporated into the research design. This review highlights the major strengths and weaknesses of the most commonly used animal models of these conditions in preclinical stroke research. The goal is to provide guidance in choosing, reporting, and executing appropriate disease models that will be subjected to different models of stroke injury.

Entities:  

Keywords:  Diabetes; Hypertension; Stroke

Mesh:

Year:  2016        PMID: 27026092      PMCID: PMC4929031          DOI: 10.1007/s12975-016-0464-8

Source DB:  PubMed          Journal:  Transl Stroke Res        ISSN: 1868-4483            Impact factor:   6.829


  107 in total

Review 1.  Is the spontaneously hypertensive stroke prone rat a pertinent model of sub cortical ischemic stroke? A systematic review.

Authors:  Emma L Bailey; Colin Smith; Cathie L M Sudlow; Joanna M Wardlaw
Journal:  Int J Stroke       Date:  2011-10       Impact factor: 5.266

Review 2.  Cellular connections, microenvironment and brain angiogenesis in diabetes: Lost communication signals in the post-stroke period.

Authors:  Adviye Ergul; John Paul Valenzuela; Abdelrahman Y Fouda; Susan C Fagan
Journal:  Brain Res       Date:  2015-03-03       Impact factor: 3.252

Review 3.  Stroke, obesity and gender: a review of the literature.

Authors:  Niki Katsiki; George Ntaios; Konstantinos Vemmos
Journal:  Maturitas       Date:  2011-05-23       Impact factor: 4.342

4.  Two-kidney, two clip renovascular hypertensive rats can be used as stroke-prone rats.

Authors:  J Zeng; Y Zhang; J Mo; Z Su; R Huang
Journal:  Stroke       Date:  1998-08       Impact factor: 7.914

5.  Tumor necrosis factor-α inhibition attenuates middle cerebral artery remodeling but increases cerebral ischemic damage in hypertensive rats.

Authors:  Paulo W Pires; Saavia S Girgla; Guillermo Moreno; Jonathon L McClain; Anne M Dorrance
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-07-11       Impact factor: 4.733

6.  Hyperlipidemia exacerbates cerebral injury through oxidative stress, inflammation and neuronal apoptosis in MCAO/reperfusion rats.

Authors:  Xiao-Lu Cao; Jing Du; Ying Zhang; Jing-Ting Yan; Xia-Min Hu
Journal:  Exp Brain Res       Date:  2015-08-04       Impact factor: 1.972

7.  Lesion development and reperfusion benefit in relation to vascular occlusion patterns after embolic stroke in rats.

Authors:  Mark J R J Bouts; Ivo A C W Tiebosch; Annette van der Toorn; Jeroen Hendrikse; Rick M Dijkhuizen
Journal:  J Cereb Blood Flow Metab       Date:  2013-12-04       Impact factor: 6.200

8.  Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study.

Authors:  H B Hubert; M Feinleib; P M McNamara; W P Castelli
Journal:  Circulation       Date:  1983-05       Impact factor: 29.690

9.  Enhanced angiogenesis with dl-3n-butylphthalide treatment after focal cerebral ischemia in RHRSP.

Authors:  Song-Jie Liao; Jian-Wen Lin; Zhong Pei; Chun-Ling Liu; Jin-Sheng Zeng; Ru-Xun Huang
Journal:  Brain Res       Date:  2009-06-12       Impact factor: 3.252

Review 10.  Rational modulation of the innate immune system for neuroprotection in ischemic stroke.

Authors:  Diana Amantea; Giuseppe Micieli; Cristina Tassorelli; María I Cuartero; Iván Ballesteros; Michelangelo Certo; María A Moro; Ignacio Lizasoain; Giacinto Bagetta
Journal:  Front Neurosci       Date:  2015-04-29       Impact factor: 4.677

View more
  37 in total

Review 1.  What Do Experimental Models Teach Us About Comorbidities in Stroke?

Authors:  Sunghee Cho; Jiwon Yang
Journal:  Stroke       Date:  2018-01-08       Impact factor: 7.914

2.  Cytoprotective Drug-Tissue Plasminogen Activator Protease Interaction Assays: Screening of Two Novel Cytoprotective Chromones.

Authors:  Paul A Lapchak; Jacqueline M Lara; Paul D Boitano
Journal:  Transl Stroke Res       Date:  2017-04-12       Impact factor: 6.829

3.  Precision Stroke Animal Models: the Permanent MCAO Model Should Be the Primary Model, Not Transient MCAO.

Authors:  Devin W McBride; John H Zhang
Journal:  Transl Stroke Res       Date:  2017-07-17       Impact factor: 6.829

4.  Translational Stroke Research Guideline Projections: The 20/20 Standards.

Authors:  Paul A Lapchak; John H Zhang
Journal:  Transl Stroke Res       Date:  2017-04-06       Impact factor: 6.829

5.  Can Quality Improvement Tools Overcome the Translational Roadblock-the Vital Influence of the Researcher.

Authors:  Serge Marbacher
Journal:  Transl Stroke Res       Date:  2017-02-24       Impact factor: 6.829

6.  Translational Stroke Research Opportunities and a Strategy to Develop Effective Cytoprotection.

Authors:  Paul A Lapchak
Journal:  Transl Stroke Res       Date:  2017-03-08       Impact factor: 6.829

7.  To Improve Translational Research in Subarachnoid Hemorrhage.

Authors:  Hidenori Suzuki; Fumi Nakano
Journal:  Transl Stroke Res       Date:  2017-06-16       Impact factor: 6.829

8.  Data Standardization and Quality Management.

Authors:  Paul A Lapchak; John H Zhang
Journal:  Transl Stroke Res       Date:  2017-03-10       Impact factor: 6.829

Review 9.  The High Cost of Stroke and Stroke Cytoprotection Research.

Authors:  Paul A Lapchak; John H Zhang
Journal:  Transl Stroke Res       Date:  2016-12-30       Impact factor: 6.829

Review 10.  Translational MR Neuroimaging of Stroke and Recovery.

Authors:  Emiri T Mandeville; Cenk Ayata; Yi Zheng; Joseph B Mandeville
Journal:  Transl Stroke Res       Date:  2016-08-31       Impact factor: 6.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.